Enanta Pharma (ENTA) Reports Q2 EPS of $0.20

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Enanta Pharma (ENTA) Reports Q2 EPS of $0.20

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019

May 7, 2019 4:00 PM EDT

Webcast and Conference Call today at 4:30 p.m. ET

Data from Phase 2a RSV program anticipated mid-2019 and Phase 2a NASH program by the end of third quarter of calendar 2019 Royalty revenue for the quarter was $39.6 million Cash and marketable securities totaled $386.7 million at March 31, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases,... More